Exact Mass: 398.1608
Exact Mass Matches: 398.1608
Found 175 metabolites which its exact mass value is equals to given mass value 398.1608
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
BENZOYLARGININE NITROANILIDE
D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D002863 - Chromogenic Compounds D004396 - Coloring Agents
Methyl (3x,10R)-dihydroxy-11-dodecene-6,8-diynoate 10-glucoside
Methyl (3x,10R)-dihydroxy-11-dodecene-6,8-diynoate 10-glucoside is found in root vegetables. Methyl (3x,10R)-dihydroxy-11-dodecene-6,8-diynoate 10-glucoside is a constituent of Helianthus tuberosus (Jerusalem artichoke). Constituent of Helianthus tuberosus (Jerusalem artichoke). Methyl (3x,10R)-dihydroxy-11-dodecene-6,8-diynoate 10-glucoside is found in root vegetables.
Methyl 3,4-dihydroxy-5-prenylbenzoate 3-glucoside
Methyl 3,4-dihydroxy-5-prenylbenzoate 3-glucoside is found in pomes. Methyl 3,4-dihydroxy-5-prenylbenzoate 3-glucoside is a constituent of apple leaves (Malus domestica). Constituent of apple leaves (Malus domestica). Methyl 3,4-dihydroxy-5-prenylbenzoate 3-glucoside is found in pomes.
Eletriptan N-oxide
Eletriptan N-oxide is a metabolite of eletriptan. Eletriptan (also known as eletriptan hydrobromide) is a second generation triptan drug intended for treatment of migraine headaches. It is used as an abortive medication, blocking a migraine attack which is already in progress. Eletriptan is marketed and manufactured by Pfizer Inc. It is sold in the US and Canada under the brand name Relpax, and in several other countries under the brand name Relert. (Wikipedia)
BENZOYLARGININE NITROANILIDE
D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D002863 - Chromogenic Compounds D004396 - Coloring Agents
Benzenesulfonamide, 2-(cyclohexylamino)-N-(((1,1-dimethylethyl)amino)carbonyl)-5-nitro-
Camostat
COVID info from Guide to PHARMACOLOGY, clinicaltrial, clinicaltrials, clinical trial, clinical trials, COVID-19 Disease Map B - Blood and blood forming organs > B02 - Antihemorrhagics > B02A - Antifibrinolytics > B02AB - Proteinase inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
(3alpha,4beta,7alpha,8alpha)-12,13-Epoxytrichothec-9-ene-3,4,7,8,15-pentol 4,15-diacetate
2-amino-5-[2-[[(3S)-2,3-dihydroxy-2-[(1S)-1-hydroxyethyl]butanoyl]oxymethyl]anilino]-5-oxopentanoic acid
3-ethyl-6-(4-O-methyl-beta-D-glucopyranosyloxy)-8-hydroxy-7-methyl-3,4-dihydroisocoumarin
2-(4,5-dihydroxy-7,7a-dimethyl-2-oxo-5,6,7,7b-tetrahydro-4H-naphtho[1,2-b]oxiren-1a-yl)prop-2-enyl 2,3,4-trihydroxybutanoate
C18H26N2O8_1,5-Dideoxy-3-C-({[2-(gamma-glutamylamino)benzyl]oxy}carbonyl)-L-arabinitol
Ala Asp Gly His
Ala Asp His Gly
Ala Gly Asp His
Ala Gly His Asp
Ala His Asp Gly
Ala His Gly Asp
Asp Ala Gly His
Asp Ala His Gly
Asp Gly Ala His
Asp Gly His Ala
Asp His Ala Gly
Asp His Gly Ala
Glu Gly Gly His
Glu Gly His Gly
Glu His Gly Gly
Gly Ala Asp His
Gly Ala His Asp
Gly Asp Ala His
Gly Asp His Ala
Gly Glu Gly His
Gly Glu His Gly
Gly Gly Glu His
Gly Gly His Glu
Gly His Ala Asp
Gly His Asp Ala
Gly His Glu Gly
Gly His Gly Glu
His Ala Asp Gly
His Ala Gly Asp
His Asp Ala Gly
His Asp Gly Ala
His Glu Gly Gly
His Gly Ala Asp
His Gly Asp Ala
His Gly Glu Gly
His Gly Gly Glu
Methyl 3,4-dihydroxy-5-prenylbenzoate 3-glucoside
Methyl (3x,10R)-dihydroxy-11-dodecene-6,8-diynoate 10-glucoside
N5-(2-((((S)-2,3-dihydroxy-2-((S)-1-hydroxyethyl)butanoyl)oxy)methyl)phenyl)glutamine
2-Methyl-N-{4-[(5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)car bonyl]phenyl}benzamide
1,5-divinyl-3,3-diphenyl-1,1,5,5-tetramethyltrisiloxane
2-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-4-oxobutyl]benzo[de]isoquinoline-1,3-dione
2-((S)-2-((S)-2-Amino-3-(1H-imidazol-4-yl)propanamido)-3-(1H-indol-3-yl)propanamido)acetic acid
4-{[5-Chloro-4-(1h-Indol-3-Yl)pyrimidin-2-Yl]amino}-N-Ethylpiperidine-1-Carboxamide
1,3,4,9-Tetrahydro-2-(hydroxybenzoyl)-9-[(4-hydroxyphenyl)methyl]-6-methoxy-2H-pyrido[3,4-B]indole
Camostat
COVID info from Guide to PHARMACOLOGY, clinicaltrial, clinicaltrials, clinical trial, clinical trials, COVID-19 Disease Map B - Blood and blood forming organs > B02 - Antihemorrhagics > B02A - Antifibrinolytics > B02AB - Proteinase inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
4-(1H-indol-3-yl)butanoic acid [2-(4-amino-1,3-dimethyl-2,6-dioxo-5-pyrimidinyl)-2-oxoethyl] ester
N-((S,E)-5-Phenyl-1-(phenylsulfonyl)pent-1-en-3-yl)pyrrolidine-2-carboxamide
7-hydroxy-4-(4-methoxyphenyl)-4,4,5-trimethyl-2-spiro[1,3-diazinane-6,2-3,4-dihydro-2H-1-benzopyran]thione
N-[2-(4-chlorophenyl)ethyl]-2-[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]acetamide
methyl 3-(4-chlorophenyl)-3-{[N-(isopropoxycarbonyl)valyl]amino}propanoate
2-(4,5-dihydroxy-7,7a-dimethyl-2-oxo-5,6,7,7b-tetrahydro-4H-naphtho[1,2-b]oxiren-1a-yl)prop-2-enyl 2,3,4-trihydroxybutanoate
2-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide
2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide
2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide
2-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide
[(3aR,4R,9bR)-1-(4-methylphenyl)sulfonyl-8-[(E)-prop-1-enyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-4-yl]methanol
(6R,7S,8S)-7-[4-(2-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-(2-methoxy-1-oxoethyl)-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8S)-7-[4-(2-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-(2-methoxy-1-oxoethyl)-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8S)-7-[4-(2-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-(2-methoxy-1-oxoethyl)-1,4-diazabicyclo[4.2.0]octan-2-one
2-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide
2-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide
2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide
2-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide
[(3aS,4S,9bS)-1-(4-methylphenyl)sulfonyl-8-[(E)-prop-1-enyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-4-yl]methanol
(6R,7S,8R)-7-[4-(2-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-(2-methoxy-1-oxoethyl)-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7R,8R)-7-[4-(2-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-(2-methoxy-1-oxoethyl)-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8R)-7-[4-(2-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-(2-methoxy-1-oxoethyl)-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8R)-7-[4-(2-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-(2-methoxy-1-oxoethyl)-1,4-diazabicyclo[4.2.0]octan-2-one
3,4,5-Trihydroxy-6-[5-(4-methoxyphenyl)-2-methyl-3-oxopentoxy]oxane-2-carboxylic acid
3,4,5-Trihydroxy-6-[5-(4-methoxyphenyl)-2-methyl-3-oxopentan-2-yl]oxyoxane-2-carboxylic acid
3,4,5-Trihydroxy-6-[1-(4-methoxyphenyl)-4-methyl-3-oxopentoxy]oxane-2-carboxylic acid
3,4,5-Trihydroxy-6-[1-(4-methoxyphenyl)-4-methyl-3-oxopentan-2-yl]oxyoxane-2-carboxylic acid
Didesmethyl cariprazine
Didesmethyl cariprazine is a metabolite of Cariprazine and acts as the predominant circulating active moiety. Didesmethyl cariprazine has a long half-life of 1-3 weeks. Cariprazine is a antipsychotic agent candidate that exhibits high affinity for the D3 and D2 receptors, and moderate affinity for the 5-HT1A receptor[1].